Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

March 20, 2019

Removing Lymph Nodes Does Not Improve Survival Outcomes of Advanced Ovarian Cancer Patients, Trial Shows

News

Women with advanced ovarian cancer who underwent a complete resection of their tumor and have normal lymph nodes do not have better survival outcomes if the lymph nodes surrounding the ... Read more

March 11, 2019

Mirvetuximab Soravtansine Fails to Delay Disease Progression in FRα-positive Ovarian Cancers, Trial Shows

News

Mirvetuximab soravtansine, an investigational antibody-drug conjugate targeting the folate receptor alpha (FRα) protein, was no better than chemotherapy at delaying disease progression or death in ovarian cancer patients included ... Read more

February 13, 2019

Lynparza Plus Weekly Chemotherapy May Help Patients with Advanced Disease, Phase 1/2 Study Finds

News

A combination of oral Lynparza (olaparib) and weekly chemotherapy can be safely given to heavily treated ovarian cancer patients and shows signs of efficacy, particularly among those with BRCA mutations, ... Read more

February 8, 2019

IMV Advances Phase 1b/2 Trial of DPX-Survivac Following Positive Feedback from FDA

News

IMV has completed an amendment to the protocol of its Phase 1/2 clinical trial testing a triple combination of DPX-Survivac, epacadostat, and low-dose chemotherapy in recurrent ovarian cancer. The company ... Read more

February 1, 2019

Alisertib-Taxol Combo Shows Promise in Recurrent Ovarian Cancer

News

A combination of the investigational treatment alisertib and weekly Taxol (paclitaxel) showed promising anti-tumor activity in ovarian cancer patients treated in a Phase 1/2 trial, warranting further studies of the ... Read more

January 28, 2019

Report: Imported Liposomal Doxorubicin Yields Similar Outcomes as Approved OC Formulation

News

A non-approved formulation of pegylated liposomal doxorubicin — called Lipodox — seems to lead to similar response rates and time to disease progression in ovarian cancer patients as the approved Doxil ... Read more

January 16, 2019

Triple Combination Works Well in Recurrent Ovarian Cancer with Smaller Tumors, Study Shows

News

The size of tumors in patients with recurrent ovarian cancer seems to predict responses to a triple combination treatment composed of IMV‘s lead candidate DPX-Survivac, Incyte’s experimental epacadostat, and low-dose chemotherapy, a ... Read more

January 7, 2019

BRACAnalysis CDx Approved in US as Companion Diagnostic Test for First-line Lynparza Treatment

News

Myriad Genetics‘ BRACAnalysis CDx has been approved by the U.S. Food and Drug Administration as a companion diagnostic test to identify women with ovarian cancer eligible for first-line maintenance treatment with Lynparza ... Read more

November 30, 2018

First Patient Dosed in Phase 1b Trial of Sitravatinib-Tislelizumab Combo for Advanced Solid Tumors

News

A Phase 1b clinical trial studying a combination of Mirati Therapeutics‘ small molecule inhibitor sitravatinib and BeiGene‘s immune checkpoint inhibitor tislelizumab has begun dosing patients. The open-label, multicenter trial (NCT03666143), expected to ... Read more

November 9, 2018

Zejula Leads to Fewer Side Effects Than Previously Reported, Real-world Study Suggests

News

Ovarian cancer patients who receive Zejula (niraparib) after responding to platinum-based chemotherapy experience fewer adverse effects in a real-world setting than was reported in a Phase 3 clinical trial, a ... Read more

Pin It on Pinterest